Repligen Corp RGEN:NASDAQ

Last Price$265.30Cboe Real-Time Last Sale as of 10:16AM ET 10/18/21
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-1.62(0.61%)
Bid (Size)$264.11 (100)
Ask (Size)$265.40 (20)
Day Low / High$263.40 - 268.04
Volume18.7 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 10/18/2021

 

Repligen Corp ( NASDAQ )

Price: $265.30
Change: -1.62 (0.61%)
Volume: 18.7 K
10:16AM ET 10/18/2021
 
 

Biohaven Pharmaceutical Holding Company Ltd ( NYSE )

Price: $133.27
Change: -0.34 (0.25%)
Volume: 55.6 K
10:17AM ET 10/18/2021
 
 

Allakos Inc ( NASDAQ )

Price: $105.69
Change: -1.79 (1.67%)
Volume: 5.6 K
10:13AM ET 10/18/2021
 
 

Karuna Therapeutics Inc ( NASDAQ )

Price: $122.56
Change: -1.21 (0.98%)
Volume: 1.9 K
10:16AM ET 10/18/2021
 
 

Reata Pharmaceuticals Inc ( NASDAQ )

Price: $97.09
Change: -1.35 (1.37%)
Volume: 15.6 K
10:15AM ET 10/18/2021
 

Read more news Recent News

Exane BNP Paribas Starts Repligen at Outperform with $330 Price Target
9:25AM ET 10/14/2021 MT Newswires

Repligen (RGEN) has an average investment rating of buy among analysts polled by Capital IQ, with a price target range of $232 to $368. (MT Newswires...

Craig Hallum Adjusts Repligen PT to $368 From $258, Maintains Buy Rating
11:11AM ET 9/27/2021 MT Newswires

Repligen (RGEN) has an average rating of Buy and price targets ranging from $232 to $368, according to analysts polled by Capital IQ. (MT Newswires covers...

KeyBanc Raises Price Target on Repligen to $335 From $255, Keeps Overweight Rating
7:25AM ET 9/17/2021 MT Newswires

Repligen (RGEN) has an average investment rating of buy and price targets ranging from $232 to $335, according to analysts polled by Capital IQ. (MT...

Repligen to Acquire Chromatography Developer Avitide in $150 Million Cash-And-Stock Deal
8:26AM ET 9/16/2021 MT Newswires

Repligen (RGEN) said Thursday it has agreed to acquire privately held chromatography developer Avitide Inc. for about $150 million in cash and stock. The...

View all Commentary and Analysis

The Landslide Portfolio
8:18PM ET 9/14/2021 Seeking Alpha

Don't Expect Much From The Fed At Virtual Jackson Hole
5:31AM ET 8/27/2021 Seeking Alpha

Horizon Therapeutics Will Offer Above Average Returns
3:17PM ET 8/12/2021 Seeking Alpha

Danaher's Growth Machine Keeps On Roaring, With No Slowdown In Sight For Bioproduction
6:46PM ET 8/06/2021 Seeking Alpha

Company Profile

Business DescriptionRepligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA. View company web site for more details
Address41 Seyon Street
Waltham, Massachusetts 02453
Phone+1.781.250.0111
Number of Employees548
Recent SEC Filing09/13/20214
President, Chief Executive Officer & DirectorTony J. Hunt
Senior Vice President-Global Operations & ITJames R. Bylund
Chief Financial OfficerJon K. Snodgres
Senior Vice President-Research & DevelopmentRalf Kuriyel

Company Highlights

Price Open$266.78
Previous Close$266.92
52 Week Range$162.29 - 327.32
Market Capitalization$14.6 B
Shares Outstanding54.9 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement10/28/2021

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings149.12
Earnings per Share$1.91
Beta vs. S&P 500N/A
Revenue$194.0 M
Net Profit Margin19.65%
Return on Equity6.88%

Analyst Ratings as of 10/13/2021

Buy
8
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset